Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in ...

Class A shares of the Alger Spectra Fund outperformed the Russell 3000 Growth Index during the fourth quarter of 2024. Read ...

The popular home expert has grown close to fans' hearts for another reason, too. Here she shares about the habits, and the ...

Its portfolio includes innovative drugs like Mounjaro, Zepbound, Trulicity, Jardiance (diabetes and obesity), Taltz (psoriasis), Emgality (migraines), and Verzenio (breast cancer). Shares ...

Large-cap stocks are stocks issued by corporations that have major influence over the economy. The “cap” in large-cap refers to the company’s “market capitalization,” which is equal to ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer ...